Screener
Protalix BioTherapeutics, Inc. PLX Q4 2025 Annual earnings
Reported March 18, 2026 · Before market open
Revenue$9.1MMiss by $9.2M
EPS-$0.07Miss by $0.08
Revenue estimate$18.3M
EPS estimate$0.01
Next report
Nov 12, 2026 (in 2 months)Revenue estimate$13.4M
EPS estimate-$0.02
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Protalix BioTherapeutics, Inc. report Q4 2025 earnings?
- Protalix BioTherapeutics, Inc. (PLX) reported Q4 2025 earnings on March 18, 2026 before market open.
- What were Protalix BioTherapeutics, Inc.'s Q4 2025 revenue and EPS?
- Protalix BioTherapeutics, Inc. reported revenue of $9.1M and eps of $-0.07 for Q4 2025.
- Did Protalix BioTherapeutics, Inc. beat estimates in Q4 2025?
- Revenue missed the consensus estimate of $18.3M by $9.2M. EPS missed the consensus estimate of $0.01 by $0.08.
- How did Protalix BioTherapeutics, Inc.'s Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 49.9% from $18.2M a year earlier.
- Where can I find Protalix BioTherapeutics, Inc.'s Q4 2025 SEC filings?
- You can read the 8-K earnings release (0001104659-26-029846) and the 10-K periodic report (0001104659-26-029858) directly on SEC EDGAR. The filing index links above go to sec.gov.
